---
sectionTitle: "Emerging Opportunities to Streamline Cancer Drug Development"
title: Agenda
template: left_nav_sub_sections
linktext: Agenda
sortOrder: 3
description: "Emerging Opportunities to Streamline Cancer Drug Development - Meeting Agenda"
---

<table class="agenda-table">
<tbody>
<tr><td>

**8:30**</td><td>

**Registration**

</td></tr>
<tr><td>

**8:30**

</td><td>

**Welcome and Introductions**

</td></tr>
<tr><td>

**9:10**

</td><td>

**Session 1, Part 1: Bringing Drugs that Add Value to Market Faster**

**Presentation: Richard Pazdur, MD,** Acting Director, Oncology Center of Excellence, U.S. Food and Drug Administration (15 min)

**Moderated Discussion** (40 min)

</td></tr>
<tr><td>

**10:10**

</td><td>

**Break**

</td></tr>
<tr><td>

**10:25**

</td><td>

**Session 1, Part 2: Bringing Drugs that Add Value to Market Faster**

</td></tr>
<tr><td>

**11:25**

</td><td>

**Session 2, Part 1: Accelerating Throughput and Learning from Clinical Trials**

**Presentation: Lisa LaVange, PhD,** Director, Office of Biostatistics, Center for Drug Evaluation and Research, U.S. Food and Drug Administration (10 min)

</td></tr>
<tr><td>

**11:40**

</td><td>

**Public Comment**

</td></tr>
<tr><td>

**11:45**

</td><td>

**Lunch**

</td></tr>
<tr><td>

**12:45**

</td><td>

**Session 2, Part 2: Accelerating Throughput and Learning from Clinical Trials**

**Presentation: James Zwiebel, MD,** Chief, Investigational Drug Branch, Cancer Therapy Evaluation Program, National Cancer Institute (10 min)

**Moderated Discussion** (60 min)

</td></tr>
<tr><td>

**1:55**

</td><td>

**Break**

</td></tr>
<tr><td>

**2:10**

</td><td>

**Session 3: Evaluating and Approving Combination Therapies**

**Presentation: Gary Gilliland, MD, PhD,** President and Director, Fred Hutchinson Cancer Research Center (10 min)

**Presentation: Roy Baynes, MD, PhD,** Senior Vice President and Head, Global Clinical Development, and Chief Medical Officer, Merck Research Laboratories (10 min)

**Moderated Discussion** (60 min)

</td></tr>
<tr><td>

**3:30**

</td><td>

**Conclusions and Cross-Cutting Recommendations**

</td></tr>
<tr><td>

**3:45**

</td><td>

**Public Comment**

</td></tr>
<tr><td>

**3:50**

</td><td>

**Wrap-Up and Next Steps**

</td></tr>
<tr><td>

**4:00**

</td><td>

**Adjourn**

</td></tr>
</tbody></table>
